{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:17:19Z","timestamp":1794014239613,"version":"4.8.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.drudis.2026.104688","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:49:52Z","timestamp":1777582192000},"page":"104688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Building and managing a complex drug discovery consortium: insights from the tuberculosis drug accelerator"],"prefix":"10.1016","volume":"31","author":[{"given":"Kelsey L.","family":"Briggs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-0208","authenticated-orcid":false,"given":"Steven J.","family":"Berthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104688_b0005","article-title":"Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006\u20132022)","volume":"30","author":"Schuhmacher","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104688_b0010","unstructured":"World Health Organization, Global tuberculosis report 2025, 2025. Accessed 4 April 2026, World Health Organization; Geneva https:\/\/www.who.int\/publications\/i\/item\/9789240116924."},{"key":"10.1016\/j.drudis.2026.104688_b0015","unstructured":"Dissanayake M. Breaking down silos: how combined expertise is shaping the future of drug discovery. Drug Discovery News. Accessed 29 April 2025. https:\/\/www.drugdiscoverynews.com\/breaking-down-silos-how-combined-expertise-is-shaping-the-future-of-drug-discovery-16345; 2025."},{"key":"10.1016\/j.drudis.2026.104688_b0020","unstructured":"Tuberculosis Drug Accelerator-Home. Accessed 4 April 2026. https:\/\/www.tbdrugaccelerator.org\/; 2026."},{"key":"10.1016\/j.drudis.2026.104688_b0025","unstructured":"Global Biodefense Staff. Top pharma and research institutes partner for \u2018TBDA\u2019. Accessed 27 June 2012. https:\/\/globalbiodefense.com\/2012\/06\/27\/top-pharma-and-research-institutes-partner-for-tb-drug-accelerator\/; 2012."},{"key":"10.1016\/j.drudis.2026.104688_b0030","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41591-021-01442-2","article-title":"The tuberculosis drug accelerator at year 10: what have we learned?","volume":"27","author":"Aldridge","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104688_b0035","unstructured":"Tuberculosis Drug Accelerator-Clinical-Trials. Accessed 4 April 2026. https:\/\/www.tbdrugaccelerator.org\/research\/clinical-trials\/; 2026."},{"key":"10.1016\/j.drudis.2026.104688_b0040","unstructured":"Tuberculosis Drug Accelerator-Cooperation-Sharing-Agreement. Accessed 4 April 2026. https:\/\/www.tbdrugaccelerator.org\/tbda-cooperation-sharing-agreement\/; 2026."},{"key":"10.1016\/j.drudis.2026.104688_b0045","unstructured":"Collaborative Drug Discovery-Home. Accessed 4 April 2026. https:\/\/www.collaborativedrug.com\/; 2026."},{"key":"10.1016\/j.drudis.2026.104688_b0050","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1021\/acsptsci.3c00034","article-title":"DAIKON: a data acquisition, integration, and knowledge capture web application for target-based drug discovery","volume":"6","author":"Rath","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.drudis.2026.104688_b0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrmicro3523","article-title":"Cooperative development of antimicrobials: looking back to look ahead","volume":"13","author":"Nathan","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.drudis.2026.104688_b0060","unstructured":"MediaRoom A. Seven pharmaceutical companies join academic researchers to speed TB drug discovery. Abbott MediaRoom. Accessed 6 July 2012. https:\/\/abbott.mediaroom.com\/2012-07-06-Seven-Pharmaceutical-Companies-Join-Academic-Researchers-to-Speed-TB-Drug-Discovery; 2012."},{"key":"10.1016\/j.drudis.2026.104688_b0065","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3389\/fphar.2017.00681","article-title":"Target identification of Mycobacterium tuberculosis phenotypic hits using a concerted chemogenomic, biophysical, and structural approach","volume":"8","author":"Mugumbate","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104688_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125022","article-title":"Protein targets in Mycobacterium tuberculosis and their inhibitors for therapeutic implications: a narrative review","volume":"243","author":"Sreelatha","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104688_b0075","first-page":"853","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"20","author":"Waring","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104688_b0080","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.drudis.2013.11.014","article-title":"Reducing attrition in drug development: smart loading preclinical safety studies","volume":"19","author":"Roberts","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104688_b0085","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00090-23","article-title":"Novel synergies and isolate specificities in the drug interaction landscape of Mycobacterium abscessus","volume":"67","author":"Van","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2026.104688_b0090","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/s41591-025-03742-3","article-title":"Strategies for shortening tuberculosis therapy","volume":"31","author":"Dartois","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104688_b0095","unstructured":"Malaria Drug Accelerator-Home. Accessed 4 April 2026. https:\/\/www.malariada.org\/; 2026."},{"key":"10.1016\/j.drudis.2026.104688_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003987","article-title":"A proposed target product profile and developmental cascade for new cryptosporidiosis treatments","volume":"9","author":"Huston","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.drudis.2026.104688_b0105","unstructured":"PR Newswire-News releases. Accessed 4 April 2026. https:\/\/www.prnewswire.com\/news-releases\/eisai-announces-continued-support-of-initiatives-for-the-elimination-of-lymphatic-filariasis-300441491.html#:\u223c:text=In%20addition%2C%20Eisai%20co%2Destablished,patients%20suffering%20from%20these%20diseases; 2026."},{"key":"10.1016\/j.drudis.2026.104688_b0110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/tropicalmed4030108","article-title":"Advances in antiwolbachial drug discovery for treatment of parasitic filarial worm infections","volume":"4","author":"Bakowski","year":"2019","journal-title":"Trop Med Infect Dis"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:40:50Z","timestamp":1789504850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1359644626000930"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104688","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Building and managing a complex drug discovery consortium: insights from the tuberculosis drug accelerator","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104688"}}